ClinicalTrials.Veeva

Menu

Lord´s Procedure Versus Sclerotherapy for Testicular Hydrocele; a Randomized Controlled Study

U

Umeå University

Status

Unknown

Conditions

Testicular Hydrocele

Treatments

Procedure: Lord´s procedure
Procedure: Sclerotherapy

Study type

Interventional

Funder types

Other

Identifiers

NCT02082613
JLL-378961

Details and patient eligibility

About

This study will compare a minimal invasive operation in local anesthesia with sclerotherapy for symptomatic testicular hydrocele within 6 months after randomization. Thirty days complication rates will be assessed. The hypothesis is that surgery will lead to faster cure while sclerotherapy would be cheaper and have less complications.

Full description

Testicular hydrocele is a common disorder even though it´s exact prevalence is unknown. In areas with filariasis it´s endemic.

Hydrocele is a benign condition where fluid accumulates in between two layers of tunica vaginalis (embryologically, the peritoneum), surrounding the testicle. The cause is unknown but inflammatory conditions is believed to induce these changes. The pathogenesis of hydrocele is believed to be a nonbalanced secretion and resorption of fluid.

Diagnosis of hydrocele is easy since the patient presents with an enlarged scrotum and clinical investigation including palpation and transillumination of the scrotum confirms the diagnosis. A scrotal ultrasound might be indicated to rule out a malignancy or if the diagnosis is unclear.

Treatment for hydrocele is only indicated when the patient has symptoms since all treatment modalities carries risk of complications, such as hematoma, infection, pain and even infertility concerns has been raised.

Operative management is considered the golden standard of treatment when considering recurrence but less invasive procedures such as sclerotherapy is frequently used, mainly due to cost and complications issues.

Lord´s procedure has in several series shown low frequency of complications and excellent recurrence rates. However, Lord´s procedure and sclerotherapy has not been tested head to head and the optimal treatment for hydrocele is yet to be determined.

This study aims to compare these techniques and evaluate the results within 1 year after randomization on cure, complication rates and various secondary descriptive outcomes.

The investigators aim to adhere to CONSORT.

Enrollment

200 estimated patients

Sex

Male

Ages

40+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Symptomatic testicular hydrocele, with more than 2 points on a validated inguinal botherscore (Inguinal Pain Questionnaire, IPQ)
  • More than 40ml of hydrocele fluid
  • Age>40 years
  • Completed reproduction
  • Oral and written consent to participate in the study
  • American Association of Anesthesiology (ASA) grade≤ 3

Exclusion criteria

  • Other ipsilateral scrotal disease (tumour, ongoing inflammatory disease of the scrotum,)
  • Ongoing urinary infection
  • Ipsilateral inguinal hernia
  • Ascites
  • Paternity wish
  • Not possible to drain the hydrocele fully
  • Opaque fluid drained on emptying the hydrocele
  • Bilateral hydrocele where both sides has symptom score more than 2p on IPQ.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

200 participants in 2 patient groups

Lord´s procedure
Experimental group
Description:
Lord´s procedure for testicular hydrocele, under local anesthesia in a conventional operation room, under sterile conditions
Treatment:
Procedure: Lord´s procedure
Sclerotherapy
Active Comparator group
Description:
Sclerotherapy with 4 ml of polidocanol 30mg/ml after complete emptying of the hydrocele. With or without local anesthesia, not performed in an operation room.
Treatment:
Procedure: Sclerotherapy

Trial contacts and locations

7

Loading...

Central trial contact

Pär Nordin, Ph.D, M.D; Karl-Johan Lundström, M.D

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems